Arch Therapeutics (ARTH) Downgraded by Ifs Securities to “Outperform”

Arch Therapeutics (OTCMKTS:ARTH) was downgraded by analysts at Ifs Securities from a “strong-buy” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday, March 14th.

A number of other research firms also recently issued reports on ARTH. Zacks Investment Research raised Arch Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. HC Wainwright set a $3.00 price target on Arch Therapeutics and gave the company a “buy” rating in a research report on Tuesday, December 19th. Finally, ValuEngine cut Arch Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $2.17.

Arch Therapeutics stock traded up $0.01 during mid-day trading on Wednesday, reaching $0.28. 172,850 shares of the company’s stock were exchanged, compared to its average volume of 212,942. Arch Therapeutics has a one year low of $0.25 and a one year high of $0.89.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at

About Arch Therapeutics

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply